Supply Chain Intelligence

Lite Strategy, Inc. Supply Chain

LITS supply chain intelligence for Lite Strategy, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LITS ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
12Customers
1Debt Items
20Related Chains

Lite Strategy, Inc. Suppliers

TickerNameConfidenceEvidence
GSR-MARKETS-LTD GSR-MARKETS-LTD 92% We enter into contracts with GSR Markets Ltd (GSR Markets), an affiliate of GSR Strategies LLC (GSR or Asset Manager), in which we write covered call options on certain of our LTC holdings (Covered C…
GSR-STRATEGIES-LLC GSR-STRATEGIES-LLC 92% We enter into contracts with GSR Markets Ltd (GSR Markets), an affiliate of GSR Strategies LLC (GSR or Asset Manager), in which we write covered call options on certain of our LTC holdings (Covered C…
ORANY ORANY 72% itionally, post-approval changes in ingredient composition, manufacturing processes or facilities, product labeling, or other areas may require submission of an NDA Supplement to the FDA for review a…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LITS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from LITS graph: Reciprocal relationship from ORAN…

Lite Strategy, Inc. Customers

TickerNameConfidenceEvidence
KKC-COMMERCIALIZATION-AGREEMENT KKC-COMMERCIALIZATION-AGREEMENT 92% We recognized revenue associated with the KKC Commercialization Agreement for the periods presented
CVM CEL-SCI Corporation 72% Reciprocal relationship from CVM graph: Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or…
CVM CEL-SCI Corporation 72% compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
URGN UroGen Pharma Ltd. 72% compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
URGN UroGen Pharma Ltd. 72% Reciprocal relationship from URGN graph: Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, o…
ANSON-ADVISORS-INC ANSON-ADVISORS-INC 62% tion. We continue to evaluate the legal issues that arise concerning transfer of personal data of residents of the European Economic Area (EEA) member states or the U.K. to the U.S. or other jurisdic…
BEIGENE-LTD BEIGENE-LTD 62% consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We re-evaluate the estimated variable…
BIOATLA-LEAP-THERAPEUTICS-CARDIFF-ONCOLOGY-MOLEC BIOATLA-LEAP-THERAPEUTICS-CARDIFF-ONCOLOGY-MOLEC 62% compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
CABLE-CAR-CAPITAL-LLC CABLE-CAR-CAPITAL-LLC 62% tion. We continue to evaluate the legal issues that arise concerning transfer of personal data of residents of the European Economic Area (EEA) member states or the U.K. to the U.S. or other jurisdic…
ONCOLOGY-G1-THERAPEUTICS-SYROS-PHARMACEUTICALS-G ONCOLOGY-G1-THERAPEUTICS-SYROS-PHARMACEUTICALS-G 62% compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
PRESAGE-BIOSCIENCES-INC PRESAGE-BIOSCIENCES-INC 62% consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We re-evaluate the estimated variable…
RESTATED-MEI-PHARMA-INC RESTATED-MEI-PHARMA-INC 62% compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …

Lite Strategy, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LITS-DEBT-10723 Warrants outstanding: 6 90% xbrl warrant detail from xbrl 2023-06-30.

Lite Strategy, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lite Strategy, Inc..

Lite Strategy, Inc. Ownership

HolderNameConfidenceEvidence
LITS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 37 tracked holders.

Lite Strategy, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
AURA Aura Biosciences, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['supplier']
AUMN Golden Minerals Company 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
AMZE Amaze Holdings, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
View LITS supply chain intel →

Explore the full interactive supply chain map for Lite Strategy, Inc..

Open LITS supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map